RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort

Detalles Bibliográficos
Autores principales: Scalzulli, Emilia, Ielo, Claudia, Luise, Cristina, Musiu, Paolo, Bisegna, Maria L., Carmosino, Ida, Assanto, Giovanni M., Martelli, Maurizio, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636318/
https://www.ncbi.nlm.nih.gov/pubmed/35737865
http://dx.doi.org/10.1182/bloodadvances.2022008158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636318/
https://www.ncbi.nlm.nih.gov/pubmed/35737865
http://dx.doi.org/10.1182/bloodadvances.2022008158

Ejemplares similares